斯洛文尼亚 - 斯洛文尼亚文 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

liofilizat za raztopino za infundiranje

斯洛文尼亚 - 斯洛文尼亚文 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

liofilizat za raztopino za infundiranje

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - imunosupresivi - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

csl behring gmbh - humani normalni imunoglobulin (scig) - sindromi imunološke pomanjkljivosti - imunski sera in imunoglobulini, - replacement therapy in adults, children and adolescents (0-18 years) in:- primary immunodeficiency syndromes with impaired antibody production (see section 4. - secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - zavrnitev presadka - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multiple myeloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocitopenična, idiopatska - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 in 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 in 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

斯洛文尼亚 - 斯洛文尼亚文 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

octapharma (ip) sprl - polispecifični imunoglobulin, humani - raztopina za injiciranje - polispecifični imunoglobulin, humani 165 mg / 1 ml - humani imunoglobulini za ekstravaskularno aplikacijo

斯洛文尼亚 - 斯洛文尼亚文 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

octapharma (ip) sprl - polispecifični imunoglobulin, humani - raztopina za injiciranje - polispecifični imunoglobulin, humani 165 mg / 1 ml - humani imunoglobulini za ekstravaskularno aplikacijo

斯洛文尼亚 - 斯洛文尼亚文 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

octapharma (ip) sprl - polispecifični imunoglobulin, humani - raztopina za injiciranje - polispecifični imunoglobulin, humani 165 mg / 1 ml - humani imunoglobulini za ekstravaskularno aplikacijo